[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Pittsburgh\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":661},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,168,0,25,[9,40,65,96,125,152,176,208,236,264,289,310,333,362,390,419,446,470,492,518,540,566,594,620,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053890","an-augmented-reality-based-system-for-neglect-detection-assessment-and-rehabilitation-100053890",false,"NCT04187131","An Augmented Reality Based System for Neglect Detection, Assessment, and Rehabilitation","Inclusion Criteria:\n\n* ages18 and older\n* acute stroke\n* admitted to inpatient rehabilitation\n* presence of neglect (Behavioral Inattention Test total score \\\u003C129, or scoring below pre-defined cutoff score in at least one of the six subtests)\n* more than 10\u002F% missed targets on the Augmented Reality Screening Test\n* intact vibration (positive test on Vibration Sensation Test)\n* intact auditory function (positive test on Auditory Sensation Test)\n* English speaking\n\nExclusion Criteria:\n\n* inability to follow one-step directions at least 80% of the time\n* current diagnosis of dementia, Parkinson's disease, multiple sclerosis, or space-occupying tumor\n* metal in the head that causes interference with the EEG system\n* self-report of previous positive photic stimulation test","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this phase is to examine the feasibility and acceptability of the Augmented Reality (AR)-based and electroencephalography (EEG)-based neglect detection and rehabilitation tool.",[26],"Stroke","RECRUITING","2026-07-09",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2023-06-01",{"date":35,"type":20},"2029-09-30",{"name":37,"class":38},"University of Pittsburgh","OTHER",2,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100054319","preventing-lymphedema-in-patients-undergoing-surgical-treatment-for-head-and-neck-cancer-through-vein-reconstruction-100054319","NCT07694726","Preventing Lymphedema in Patients Undergoing Surgical Treatment for Head and Neck Cancer Through Vein Reconstruction","Lymphedema Prevention With Facial Vein Preservation or Reconstruction During Neck Dissection for Operable Head & Neck Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Ability to comply with the study protocol, including follow up visits and additional requirements for data collection\n* Ability to provide informed consent\n* Patients requiring unilateral or bilateral neck dissection. Patients must undergo at least three level neck dissection which must include level 1B\n* Patients will undergo radiotherapy +\u002F-chemotherapy after surgery for HNC. Patients will be required to have adjuvant therapy after surgery to have similar risk of development of lymphedema.\n* No history of allergy to indocyanine green.\n\nExclusion Criteria:\n\n* Shellfish Allergy\n* Contraindication to surgery under general anesthesia\n* Prior head and neck surgery, radiation, or chemotherapy for HNC\n* Patients requiring sacrifice of the internal jugular vein or resection of neck skin for oncologic care\n* Anticipated partial or total laryngectomy\n* Pregnancy or lactation",{"count":48,"type":20},37,[23],"\\* The goal of this clinical trial is to learn if facial vein reconstruction after neck dissection works to reduce rates of lymphedema in adults getting surgical treatment for head and neck cancer.\n\nThis is a trial which aims to improve the rate of lymphedema for patients undergoing treatment for head and neck cancer. Our aim is to re-establish venous flow across the facial vein to improve lymphatic drainage after neck dissection.\n\n* The investigators will also evaluate lymphatic flow before and after facial vein reconstruction to determine if there is evidence of lymphedema.\n* The main questions this study aims to answer are:\n\n  1. Does facial vein reconstruction after neck dissection improved lymphatic flow in head and neck cancer patients?\n  2. Determine if there are changes in lymphatic flow before and after facial vein reconstruction?\n\nAfter the study is completed, the investigators will compare rates of lymphedema and quality of life in patients with facial vein preservation\u002Freconstruction as compared to previous patients treated for head and neck cancer without facial vein reconstruction.\n\nParticipants will undergo the following:\n\n1. Oncologic and reconstructive surgery as normal. No changes in cancer treatment will occur due to the study.\n2. When necessary, participants will undergo facial vein reconstruction immediately after neck dissection\n3. Visit the clinic once every 3 months for routine checkups and tests. This is typical for most patients treated for head and neck cancer including those not enrolled in the trial.\n4. Fill out short questionnaires to help understand quality of life after head and neck cancer treatment\n5. Undergo lymphography in the OR and at the 1-year mark in the office. This is a simple test performed without radiation exposure. It requires 3 very small skin injections to perform the test.",[52],"Head and Neck Cancer",[54,55,56],"head and neck cancer","head and neck lymphedema","lymphedema","NOT_YET_RECRUITING",{"date":30,"type":31},{"date":60,"type":20},"2026-07",{"date":62,"type":20},"2028-12",{"name":37,"class":38},1,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":16,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":83,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":64},"100629612","differences-in-rest-emotion-and-arousal-modulation-in-youth-100629612","NCT07476937","Differences in Rest, Emotion, and Arousal Modulation in Youth","Probing the Role of Sensory Regulation in Sleep Health and Emotion Dysregulation for Autistic Youth","DREAMY-Autism","Inclusion Criteria:\n\n1. Youth between the ages of 6 and 10 years old\n2. Caregiver-reported autism diagnosis and \\>11 on Social Communication Questionnaire\n3. Caregiver-reported bedtime resistance (\\>12 on Children's Sleep Habits Questionnaire-Autism; Sleep Initiation subscale - 3-point scale, 6 questions)\n4. Caregiver willing to participate in all bedtimes during study\n5. Stable medication use (e.g., no changes within 2 weeks)\n\nExclusion Criteria:\n\n1. Participants will be excluded if they do not understand English or are unable to travel to the lab (Pittsburgh, PA).\n2. Concurrent diagnosis of sleep apnea, narcolepsy, or major psychiatric disorder (e.g., major depression, bipolar).\n3. Unstable medication use (dose or timing).\n4. Current behavioral treatment for sleep disorder","6 Years","10 Years",{"count":76,"type":20},60,[23],"The goal of this study is to examine the relationship between sensory responsivity, bedtime arousal levels, sleep disturbances, and daytime emotion dysregulation for autistic children (ages 6-10). In a subset of children with elevated sensory responsivity, a sensory-based bedtime manipulation targeting bedtime arousal levels will be tested.",[80,81,82],"Autism","Sleep Disturbances in Children","Sleep",[84,85,86,82,87],"Sleep disturbances","Emotion Dysregulation","Sensory Processing","autism","2026-06-30",{"date":90,"type":31},"2026-07-02",{"date":92,"type":31},"2026-06-01",{"date":94,"type":20},"2030-08",{"name":37,"class":38},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":109,"conditions":110,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":39},"100627625","vasectomy-right-for-me-decision-support-tool-100627625","NCT07451067","\"Vasectomy: Right for Me?\" Decision Support Tool","Addressing Factors Related to Disparities in Vasectomy","Inclusion Criteria:\n\n* Are assigned male at birth\n* 21-55 years of age\n* Comfortable reading in English or Spanish\n* Live in the United States\n* Are considering vasectomy\n* Have not had a vasectomy\n\nExclusion Criteria:\n\n* Are not assigned male at birth\n* Are less than 21 or more than 55 years of age\n* Is not comfortable reading English nor Spanish\n* Do not live in the United States\n* Are not considering vasectomy\n* Have had a vasectomy\n* Once a racial or economic sub-group recruitment number has been reached, no other subjects fitting that ethnicity or income group will be enrolled.","MALE","21 Years","55 Years",{"count":107,"type":20},750,[23],"The goal of this trial is to learn if a web-based decision aid designed to provide evidence-based information about vasectomy and other birth control options helps improve users' decision-making about birth control. The main questions it aims to answer are:\n\n* Do people who use the decision aid have better knowledge about vasectomy?\n* Do people who use the decision aid have lower conflict with their decision?\n\nParticipants will:\n\n* Use the decision aid (if they are assigned to the intervention arm).\n* Answer survey questions about their knowledge, decision-making, interest in vasectomy, and healthcare navigation experiences.",[111,112,113,114],"Vasectomy","Contraception","Contraception Behavior","Reproductive Behavior",[111,116],"Decision aid","2026-06-29",{"date":119,"type":31},"2026-07-01",{"date":121,"type":31},"2026-06-20",{"date":123,"type":20},"2027-08",{"name":37,"class":38},{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":141,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":151,"locationsCount":39},"100579100","acceptance-and-commitment-therapy-integrated-vestibular-rehabilitation-active-rct-100579100","NCT06819904","Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE) RCT","Acceptance and Commitment Therapy Integrated Vestibular Rehabilitation (ACTIVE) for mTBI: A Targeted Randomized Controlled Trial","Inclusion Criteria:\n\n* 18-49 years of age\n* Normal\u002Fcorrected vision\n* Diagnosed with mTBI per military clinical practice guidelines (CPGs) that occurred over 8 days prior to consent as determined by a multi-domain assessment performed by a licensed healthcare professional.\n* mTBI-related symptoms and\u002For impairments in at least one or more areas, including vestibular (dizziness, imbalance), psychological health (anxiety, depression, stress), cognitive (memory problems), headache\u002Fmigraine, ocular, or sleep. as determined by self-report.\n\nExclusion Criteria:\n\n* History of vestibular disorder (e.g., benign paroxysmal positional vertigo, unilateral or bilateral vestibular hypofunction) as determined by patient self-report.\n* History of neurological disorder (e.g., epilepsy, multiple sclerosis) as determined by self-report.\n* Cervical spine injury or dysfunction (i.e., limited range of motion; ROM) as determined by self-report.\n* Previous moderate to severe TBI as determined by self-report.\n* \\\u003C 8 days following current mTBI as determined by self-report.\n* Currently pregnant as determined by self-report.","49 Years",{"count":134,"type":20},250,[23],"The primary objective of this multi-site randomized clinical trial (RCT) is to compare Acceptance and Commitment Therapy Integrated Rehabilitation (ACT) with usual care rehabilitation (CONTROL) in 250 individuals with mTBI-related symptoms attributable to mild traumatic brain injury (mTBI) treated at one of two sites (1) the University of Pittsburgh Medical Center, or (2) the Intrepid Spirit Center, Carl R. Darnall Army Medical Center, Fort Hood, Texas. Both interventions will be delivered weekly over 4 weeks. Assessments will be administered prior to the start of treatment (Baseline) and at 4-weeks, 3- and 6-months following the completion of treatment.",[138,139,140],"Concussion, Mild","Mild Traumatic Brain Injury (mTBI)","Psychological Health",[142,143,144,145],"concussion","mTBI","psychological health","treatment","2026-06-25",{"date":88,"type":31},{"date":149,"type":31},"2025-02-27",{"date":123,"type":20},{"name":37,"class":38},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":64},"100642074","the-effects-of-strength-training-on-muscle-mass-and-mental-health-in-adults-taking-obesity-medication-100642074","NCT07652333","The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication","The Effects of Strength Training on Muscle Mass and Mental Health in Adults Taking Obesity Medication: A Pilot Study","STRONG","Inclusion Criteria:\n\n* Initiating GLP-1 RAs prescribed by physician or advanced practice practitioner and willing to withhold the start of the drug until baseline assessment completed\n* Non-Smoker\n* ≥18 years old\n* Obese: Body Mass Index 30-45 kg\u002Fm² or BMI ≥27 + ≥1 weight related comorbidity; either hypertension or sleep apnea confirmed by participant self-report\n* Inactive: not meeting the current US exercise guidelines over the past 6 months\n* Capable of performing the required exercise training\n\nExclusion Criteria:\n\n* A serious heart condition, such as unstable heart disease or heart failure, irregular heartbeats that are not well controlled, severe narrowing of the heart valves, or any recent inflammation of the heart or its lining\n* Cancer requiring treatment in the past 5 years\n* Hypothyroidism\u002Fhyperthyroidism\n* Personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia Syndrome type 2 (MEN2)\n* Gastroparesis\n* Chronic\u002Fidiopathic acute pancreatitis\n* Hepatic disease or cirrhosis\n* Struggle with alcohol or other substance abuse (heavy drinking (≥4 drinks\u002Fday or ≥8 drinks\u002Fweek for women; ≥5 drinks\u002Fday or ≥15 drinks\u002Fweek for men), or who score ≥3 on the Drug Abuse Screening Test (DAST-10))\n* Diabetes (Type 1 or 2)\n* Major risk factors for coronary heart disease such as uncontrolled high blood pressure (≥160 mm Hg systolic or ≥100 mm Hg diastolic)\n* Problems with your muscles or bones that limit your ability to exercise\n* Any other medical condition that is life-threatening, can interfere with or be aggravated by the exercise training\n* Plans to be away ≥2 weeks in the next 3 months\n* Participation in any other concurrent interventional clinical trial\n* History of eating disorders or weight-loss surgery, unstable weight (±5% change in past 6 months), or use of obesity medication (e.g., such as Wegovy, Ozempic, Saxenda, Zepbound, Mounjaro) in the last 3 months\n* Inability to give informed consent\n* History of major depression or other severe psychiatric disorders (e.g., who answer \"yes\" to question 9 on PHQ-9 in the Psych\\_QoL\\_Sleep questionnaires.)\n* Pregnant or plan to become pregnant during study",{"count":161,"type":20},40,[23],"The purpose of this study is to examine the effects of resistance exercise, such as weightlifting, on retention of muscle mass and mental health in individuals taking GLP-1 RAs (an obesity medication). Resistance exercise is focused on increasing the strength of participants' muscles, such as how much participant can lift.\n\n•The duration of this study is 3 months. This includes:\n\n* Orientation session to explain study protocol, exercise program, and complete questionnaire about participants' medical history and lifestyle.\n* Two health assessments at baseline and at 3 months. These assessments include body composition, resting blood pressure, cardiovascular function, and muscular strength. Both the resistance exercise group and the control group will complete assessments at baseline and again at 3 months. After the 3-month period, individuals in the control group may choose to participate in the exercise training and complete the optional 6-month assessments.\n* Personalized resistance exercise sessions for 60 minutes per session, twice per week, for 3 months.",[165,166,167],"Muscle Composition","Obesity","Quality of Life (QOL)","2026-06-21",{"date":170,"type":31},"2026-06-24",{"date":172,"type":31},"2026-05-25",{"date":174,"type":20},"2027-05-31",{"name":37,"class":38},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":64},"100578043","machine-learning-prediction-and-reducing-overdoses-with-ehr-nudges-100578043","NCT06806163","Machine-Learning Prediction and Reducing Overdoses With EHR Nudges","mPROVEN","Inclusion Criteria:\n\n* Received an opioid prescription within the past year\n* Age 18 years or older at the time of the opioid prescription\n* At least one visit to an internal medicine or family care practice within the past year\n\nExclusion Criteria:\n\n* Diagnosis of malignant cancer within the past year\n* Enrollment in hospice care",{"count":184,"type":20},1350,[23],"The goal of this cluster randomized clinical trial is to test a clinician-targeted behavioral nudge intervention in the Electronic Health Record (EHR) for patients who are identified by a machine-learning based risk prediction model as having an elevated risk for an opioid overdose.\n\nThe clinical trial will evaluate the effectiveness of providing a flag in the EHR to identify individuals at elevated risk with and without behavioral nudges\u002Fbest practice alerts (BPAs) as compared to usual care by primary care clinicians.\n\nThe primary goals of the study are to improve opioid prescribing safety and reduce overdose risk.",[188,189,190,191],"Opioid Overdose","Opioid Use","Opioid Use Disorder","Opioids",[193,194,195,196,197,198,199,188,191],"Machine learning","Risk prediction","Behavioral nudge","Best Practice Alert","Artificial intelligence","Primary care","Electronic Health Record Platforms","2026-06-16",{"date":202,"type":31},"2026-06-17",{"date":204,"type":31},"2025-03-10",{"date":206,"type":20},"2027-02",{"name":37,"class":38},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":215,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":64},"100551289","imaging-speech-in-neurotypical-adults-and-individuals-with-cerebellar-stroke-100551289","NCT06458153","Imaging Speech in Neurotypical Adults and Individuals With Cerebellar Stroke","High-resolution Functional Imaging of Speech-induced Sensory Modulation","Inclusion Criteria:\n\nCohort 1 (neurotypical adults):\n\n* Age 18-49\n* Right-handed\n* Native English speaker\n\nCohort 2 (people with cerebellar lesions):\n\n* Age 18 or older\n* Right-handed\n* Native English speaker\n* History of cerebellar stroke\n\nCohort 3 (controls matched to Cohort 2)\n\n* Age 18 or older\n* Right-handed\n* Native English speaker\n\nExclusion Criteria:\n\nCohort 1 (neurotypical adults):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury)\n* Hearing loss, defined by pure tone thresholds \\>25 decibels (dB) hearing level (HL) at octave frequencies between 250-8000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Clinically diagnosed with or treated for a speech, language, or hearing disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant\n\nCohort 2 (people with cerebellar lesions):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury other than stroke\n* Hearing loss, defined by pure tone thresholds \\>50 dB HL at octave frequencies between 250-4000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant\n\nCohort 3 (controls matched to Cohort 2):\n\n* Presence of MRI risk factors: metal and\u002For electromagnetic devices (e.g., pacemakers, neurostimulators) in the body, previous shrapnel injuries, use of an intrauterine device containing metal, claustrophobia, pregnant or possibly pregnant\n* History of neurological \u002F neurodegenerative disease or severe brain injury (e.g., stroke or severe traumatic brain injury)\n* Hearing loss, defined by pure tone thresholds \\>50 dB HL at octave frequencies between 250-4000 Hz\n* Clinical diagnosis and\u002For treatment for schizophrenia or other psychotic disorders\n* Clinical diagnosis and\u002For treatment for neurocognitive disorders (e.g., dementia, delirium)\n* Presence of a severe and unmanaged, clinically diagnosed attention disorder\n* Clinically diagnosed with or treated for a speech, language, or hearing disorder\n* Head circumference greater than 60cm or weight greater than 300 pounds\n* History of severe claustrophobia\n* Currently pregnant",true,{"count":217,"type":20},100,[23],"The goal of this research study is to learn how the brain areas that plan and control movement interact with the areas responsible for hearing and perceiving speech in healthy adults and people who have had cerebellar strokes. The main questions it aims to answer are:\n\n1. What regions of the brain's sensory systems show changes in their activity related to speech?\n2. To what extent do these regions help listeners detect and correct speech errors?\n3. What is the role of the cerebellum (a part of the brain in the back of the head) in these activities?\n\nParticipants will be asked to complete several experimental sessions involving behavioral speech and related tests and non-invasive brain imaging using electroencephalography (EEG) and functional magnetic resonance imaging (fMRI).",[26,221],"Cerebellum",[223,224,225,226,227,228],"fmri","speech production","cerebellum","auditory-motor integration","speech motor control","neuroimaging",{"date":230,"type":31},"2026-06-18",{"date":232,"type":31},"2025-05-27",{"date":234,"type":20},"2028-07",{"name":37,"class":38},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":16,"minAge":244,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":263},"100496739","a-study-to-investigate-why-overweight-people-regain-weight-after-losing-weight-in-a-behavioral-weight-loss-program-100496739","NCT05748158","A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program","Physiology of the Weight Reduced State","POWERS","Inclusion Criteria:\n\n1. Age: 25 - \\\u003C60 years\n2. BMI: 30 - \\\u003C40 kg\u002Fm2 at the first screening visit\n3. Within 5% of current weight, for the past 6 months at the first screening visit\n4. Able to participate in ergometry testing\n5. Has a smart phone, tablet or computer with access to the internet\n\nExclusion Criteria:\n\n1. If 25-29 years old, \\> 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years\n2. If at least 30 years old, \\> 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years\n3. History of pulmonary embolus in the past 6 months\n4. Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack) within the past 6 months\n5. Current major depressive disorder or history of major depressive disorder within 2 years\n6. Any regular tobacco or nicotine use in the past year\n7. Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building\n8. Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years\n9. Presently classified as being in New York Heart Association Class II or greater or dysrhythmia\n10. Diabetes (type 1 or 2 - HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg\u002FdL) or currently taking a glucose lowering medication\n11. Thyroid disease requiring hormones or medication or TSH \\\u003C 0.5 or \\> 5 mIU\u002FL\n12. Renal disease requiring dialysis\n13. Known HIV infection\n14. ALT or AST greater than 5 times the upper limit of normal or active gall bladder disease\n15. Significant anemia (Hgb \\\u003C 10 g\u002FdL) or thrombocytopenia (platelet count \\\u003C 60,000 \u002Fmm3)\n16. Leukopenia defined as:\n\n    Males: WBC \\\u003C 3,100 \u002Fmm3 or (WBC 3,100 - \\\u003C 4,000 \u002Fmm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC \\\u003C 3,400 \u002Fmm3 or (WBC 3,400 - \\\u003C 4,000 \u002Fmm3 and at least 1 Duffy antigen (A, B) positive or no result)\n17. Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured\n18. Current or past history of anorexia nervosa or bulimia nervosa\n19. Current or past diagnosis of binge eating disorder\n20. Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)\n21. Unwillingness to abstain from marijuana\u002Fcannabis use for 3 weeks at each of the four assessment time points\n22. Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs\n23. Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months\n24. Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, steroids-including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications)\n25. Currently taking anticoagulant medication\n26. Currently enrolled in a supervised weight reduction program\n27. Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty\n28. Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (\\\u003C15% calorie as carbohydrate), very low fat (\\\u003C15% calories as fat), or strictly gluten free\n29. Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet\n30. Night or rotating shift worker\n31. Known severe allergy (e.g. anaphylaxis) to nuts or other foods\n32. Systolic blood pressure (BP) \\\u003C90 mmHg and\u002For diastolic BP \\\u003C60 mmHg on 2 measurements during the clinical screening visit.\n33. Systolic blood pressure (BP) \\>160 mmHg and\u002For diastolic BP \\>100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate \\\u003C 45 beats per minute or \\>100 on 2 measurements during the clinical screening visit.\n34. Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments\n35. Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view\n36. Known allergy to lidocaine or acetaminophen\n37. Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase\n38. Blood clotting disorder or INR \\> ULN or PT \\> ULN or (a)PTT \\> ULN\n39. Tendency to form thick or raised scars\n40. Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment\n41. At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)","25 Years","59 Years",{"count":247,"type":20},205,[23],"The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.",[166],[166,252,253,254],"Weight loss","Weight change trajectory","Lifestyle intervention","2026-06-10",{"date":257,"type":31},"2026-06-12",{"date":259,"type":31},"2023-09-29",{"date":261,"type":20},"2027-03",{"name":37,"class":38},3,{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":64},"100552647","dietary-interventions-in-cancer-patients-treated-with-immune-checkpoint-inhibitors-100552647","NCT06475807","Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors","Cancer Nutrition Study: CaNS - A Pilot Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n1. Be willing and able to provide written informed consent.\n2. Adult ≥ 18 years of age, willing and able to provide blood and stool specimen and comply with dietary modification, as well as willing to fill out study required questionnaires (paper or electronic and web-based).\n3. Patients must have any type of electronic device such as a smartphone, tablet, or computer etc that can access the internet.\n\n   Body mass index (BMI) 18.5-40 kg\u002Fm2.\n4. Self-reported willingness to adhere with dietary intervention.\n5. Self-reported willingness to comply to scheduled follow ups, fill out questionnaires\u002Ffood logs, provide stool samples and undergo venipuncture\n6. Patients who are treated or about to start treatment with standard of care anti-PD-1\u002FPD-L1 therapy will be consented for the dietary intervention study I. Early stage (IIB-IIIC) resected melanoma patient on adjuvant pembrolizumab or nivolumab.\n\n   II. Early stage (IB-IIIA) resected NSCLC patients on adjuvant pembrolizumab or atezolizumab.\n\n   III. Early stage (IB-IIIA) NSCLC patients who are surgical candidates and are treated with neoadjuvant chemotherapy plus immunotherapy (nivolumab or pembrolizumab).\n\n   a. (patients can be enrolled in the study at any point during their treatment period) IV. Stage IIIB or IIIC NSCLC after concurrent chemotherapy and radiotherapy followed by consolidation immunotherapy (durvalumab).\n\n   V. LS-SCLC after concurrent chemotherapy and radiotherapy followed by consolidation immunotherapy (durvalumab)\n7. Melanoma patients with stage IIB-IIIC, currently enrolled in a clinical trial and randomized to the standard of care arm (e.g., adjuvant nivolumab or adjuvant pembrolizumab), as permitted by the protocols of the enrolled clinical trial.\n8. Melanoma patients with a single metastatic or recurrent lesion who have undergone tumor resection and are currently receiving adjuvant treatment with nivolumab or pembrolizumab.\n9. Stage IIB-IIIA NSCLC patients currently enrolled in a clinical trial and randomized to the standard of care anti-PD1\u002Fanti-PD-L1 arm after tumor resection or stage IIIB\u002FC NSCLC or LS-SCLC patients after concurrent chemo\u002FRT enrolled in a clinical trial and randomized to the standard of care consolidation immunotherapy arm as permitted by the protocols of the enrolled clinical trial.\n\nExclusion Criteria:\n\n1. Patients receiving ICIs enrolled in a clinical trial in the experimental arm.\n2. Use of any of the following drugs within the last 4 weeks:\n\n   1. Systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral);\n   2. Oral, intravenous, intramuscular, nasal, or inhaled corticosteroids ((\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study intervention administration. Inhaled or topical steroids and adrenal replacement doses \\>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease)\n   3. Cytokines.\n   4. Methotrexate or immunosuppressive cytotoxic agents.\n   5. Regularly taking probiotics, fiber supplements, or any other medication or pre-biotic dietary supplement that could affect the study outcome as determined by the principal investigator and unable\u002Funwilling to discontinue for the study. These agents must be discontinued at least 14 days prior to the start of the diet.\n3. Current use of chronic alcohol within the last 4 weeks, defined as more than five 1.5-ounce servings of 80-proof distilled spirits, five 12-ounce servings of beer, or five 5-ounce servings of wine per day.\n4. Current consumption of fiber \\>25g (determined based on patient reported intake or baseline DHQ3 assessment) or fermented food ≥≥3 portions a day (foods\u002Fdrinks tested in the clinical trial, for example coffee beverage is considered to be a fermented drink but will not count towards the consume fermented food intake).\n5. Any major bowel resection at any time.\n6. Medical contraindications to intervention diet as determined by the treating physician.\n7. Systemic antibiotics and proton pump inhibitors (PPis) are not allowable during the study (should be discontinued \\>21 days prior). If PPIs or systemic antibiotics are initiated by the patient's treating physician, the patient should report this to the study team during the study period.\n8. Unable or unwilling to adhere schedule interventions and study procedures.\n9. History of active uncontrolled gastrointestinal disorders or diseases, including:\n\n   1. Inflammatory bowel disease (IBD), including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis.\n   2. Malabsorption (e.g active celiac disease)\n   3. Active Persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent), or Helicobacter pylori infection (untreated).",{"count":272,"type":20},70,[23],"This pilot trial will study the potential impact of two distinct dietary interventions with sequential use of high-fermented foods and high-fiber supplements on the gut microbiome and antitumor immunity in patients with melanoma and non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. The trial aims to understand how dietary changes affect the composition and function of the gut microbiome, together with immunological and metabolomic markers in serum in patients with melanoma and NSCLC who are undergoing standard-of-care treatment with a PD-1\u002FPD-L1 Inhibitors (neoadjuvant, adjuvant or consolidation)",[276],"Cancer",[278,279,280],"PD-1\u002FPD-L1 Inhibitors","inflammatory cytokines","gut microbiota","2026-06-09",{"date":283,"type":31},"2026-06-11",{"date":285,"type":31},"2024-07-17",{"date":287,"type":20},"2030-06",{"name":37,"class":38},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":309,"locationsCount":64},"100323678","mypath-story-booth-100323678","NCT03494075","MyPaTH Story Booth","Inclusion Criteria:\n\n* Over the age of 18\n\nExclusion Criteria:\n\n* Researchers will exclude individuals who are not 18 years of age or older and\u002For do not provide informed consent","99 Years",{"count":297,"type":20},2000,"OBSERVATIONAL","The MyPaTH Story Booth will use an (audio) \"document\" approach to elicit in depth experiential knowledge or perspectives from patients and caregivers by recording their personal stories.",[301],"Narrative Medicine",[303,304],"Patients","Caregivers",{"date":283,"type":31},{"date":307,"type":4},"2016-03",{"date":287,"type":20},{"name":37,"class":38},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":320,"conditions":321,"keywords":323,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":64},"100543440","liver-volume-variation-effect-on-sbrt-planning-and-delivery-for-upper-abdominal-malignancies-100543440","NCT06355895","Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies","The Effect of Liver Volume Variation on Stereotactic Body Radiation Therapy (SBRT) Planning and Delivery for Upper Abdominal Malignancies","Inclusion Criteria:\n\n• Have primary upper abdominal (pancreatic, bile duct, liver) cancer or upper abdominal metastases (liver, adrenal, upper abdominal lymph nodes) planned to undergo SBRT.\n\nExclusion Criteria:\n\n* Had prior Radiation Therapy to the liver\n* Contraindication to receipt of iodinated IV contrast for CT (such as renal insufficiency or allergy that cannot be overcome by premedication)\n* Pregnancy\u002Flactation OR woman of childbearing potential who is unable or unwilling to use adequate contraception during Radiation Therapy.\n* Inability to fast.",{"count":318,"type":20},17,[23],"Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting\u002Ffed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT.",[322],"Upper Abdominal Malignancies",[324,325],"Stereotactic Body Radiation Therapy (SBRT)","Four-Dimensional Computed Tomography","2026-06-08",{"date":283,"type":31},{"date":329,"type":31},"2024-05-16",{"date":331,"type":20},"2028-03-31",{"name":37,"class":38},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":21,"phases":343,"briefSummary":344,"conditions":345,"keywords":347,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":361},"100598625","prescribe-to-prevent-hiv-a-hybrid-trial-helping-addiction-clinics-prevent-hiv--infections-through-safer-drug-use-support-100598625","NCT07073924","Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support","Prescribe to Prevent HIV (P2PH): Enhancing Clinic-based Prescribing of Harm Reduction: A Clinical Trial to Prevent HIV and Severe Injection-related Infections Among PWID","P2PH","Patients:\n\nPre-implementation interviews (N=12), pre-implementation focus groups (N=8), and post-implementation interviews (N=10)\n\nInclusion Criteria:\n\n-Adult patients with history of active injection drug use in the past 1 year from the 4 COEs\n\nExclusion Criteria:\n\n* Ages \\\u003C18\n* If history of injection drug use \\>1 year\n* Non-English speaking\n* Pending or legal action that could prohibit or interfere with participation (Ie. incarceration)\n* Residence or discharge to a treatment facility that bans the possession of drug checking supplies\n* Acute, severe psychiatric condition in need of immediate treatment.\n\nClinical Partners:\n\nPre-implementation interviews (N=12), pre-implementation focus groups (N = 24), post-implementation surveys (N = 80), and post-implementation interviews (N=10)\n\nInclusion Criteria:\n\n-Prescribing clinicians (e.g., physicians, advanced practice providers such as nurse practitioners and physician assistants), administrators, medical assistants, and nurses from the 4 COEs\n\nExclusion Criteria:\n\n* Individuals not affiliated with the 4 COEs.\n* Staff outside the specified roles (i.e., not prescribing clinicians, administrators, medical assistants, or nurses).\n* Students, trainees, or individuals not credentialed in the eligible roles.\n* Those on extended leave or not actively working during the study period.",{"count":342,"type":20},536,[23],"In the U.S., an estimated 3.6 million people who inject drugs (PWID) face a growing yet preventable health crisis, with rising cases of serious injection-related infections (SIRI), including HIV, due to limited access to two high-priority interventions: sterile injection equipment and daily oral HIV pre-exposure prophylaxis (PrEP). Outpatient clinics represent an opportune venue to implement these interventions. Yet most clinical providers in these settings do not currently provide them, contributing to a wide gap between evidence and routine practice. The Prescribe to Prevent HIV (P2PH) trial is a participatory study designed to co-develop and pilot test a set of implementation strategies to support outpatients clinics in offering sterile injection equipment and PrEP with the goal of reducing the risk of HIV and SIRI among PWID. This study is supported by the HEAL Initiative (https:\u002F\u002Fheal.nih.gov\u002F).",[346],"People Who Use Opioids\u002FPeople With Opioid Use Disorder (OUD)",[348,349,350,351,352,353],"people who use drugs","HIV","PrEP","Opioid-Related Disorders","implementation","Substance-Related Disorders","2026-06-06",{"date":281,"type":31},{"date":357,"type":20},"2026-08-01",{"date":359,"type":20},"2028-06",{"name":37,"class":38},4,{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":369,"minAge":17,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":372,"briefSummary":373,"conditions":374,"keywords":378,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":64},"100643173","mobile-health-program-for-post-preeclampsia-hypertension-100643173","NCT07599579","Mobile Health Program for Post-Preeclampsia Hypertension","Multilevel Mobile Health Program to Improve Hypertension Among Midlife Women After Hypertensive Disorder of Pregnancy","Inclusion Criteria:\n\n* Women who had a history of HDP (either gestational HTN or preeclampsia) diagnosed by ACOG guidelines at the time of delivery at Magee-Womens Hospital between 2008 and 2015, thus 10 to 20 years from their index pregnancy complicated by HDP.\n* Evidence of current stage 2 HTN (BP ≥ 140\u002F90 mmHg with or without treatment with antihypertensive medication).\n\nExclusion Criteria:\n\n* Known clinical CVD (prior myocardial infarction, stroke, heart failure, or peripheral arterial disease).\n* Males will also be excluded from this study as it focuses on pregnancy related conditions.\n* Children will be excluded as the study is only recruiting people who are 10-20 years postpartum.","FEMALE",{"count":371,"type":20},50,[23],"Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.",[375,376,377],"Hypertension (HTN)","Preeclampsia","Hypertensive Disorders of Pregnancy (HDP)",[379,380,381,382],"hypertension","preeclampsia","coaching","home blood pressure monitoring","2026-06-04",{"date":326,"type":31},{"date":386,"type":20},"2026-06",{"date":388,"type":20},"2027-10",{"name":37,"class":38},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":16,"minAge":397,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":401,"conditions":402,"keywords":406,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":418},"100424604","open-versus-arthroscopic-stabilization-of-shoulder-instability-with-subcritical-bone-loss-the-oasis-trial-100424604","NCT04809064","Open Versus Arthroscopic Stabilization of Shoulder Instability With Subcritical Bone Loss: The OASIS Trial","OASIS","Inclusion Criteria:\n\n* Civilians and military personnel ages 17 to 50\n* Traumatic anterior shoulder dislocation\n* Associated subcritical bone loss between 10-20% less the glenoid width quantified by standard of care CT scan, MRI, or 3D-MRI scan\n* Had shoulder instability surgery using either 1) arthroscopic Bankart repair with remplissage of Hill-Sachs lesion; 2) open Bankart; or 3) Latarjet\n\nExclusion Criteria:\n\n* Chronic, non-traumatic multi-directional instability based on clinical exam\n* Concurrent shoulder injury in the involved shoulder (e.g., rotator cuff tears, motor nerve pathologies, osteoarthritis of a Samilson-Prieto grade \\>2)\n* Have a history of shoulder surgery in the involved shoulder (prior instability surgery that included any of the following and the planned procedure would be a repeat of the index procedure: 1) arthroscopic Bankart repair with a remplissage of Hill-Sachs lesion, 2) open Bankart, or 3) Latarjet \\[previous isolated arthroscopic Bankart repair only would not be an exclusion criterion\\], rotator cuff repair, intra-articular soft tissue surgery); rotator cuff repair, intra-articular soft tissue surgery)\n* Prior rotator cuff procedure on involved shoulder (including intra-articular soft tissue surgery\n* Humeral sided bone lesions (Hill-Sachs lesion) that is sufficiently large enough to render the lesion \"off-track\" even after a bony augmentation procedure would be performed\n* Neuromuscular, neurological and other movement control pathologies including seizures\n* Vascular injury associated with the shoulder trauma that compromise adequate\u002Fnormal healing or interferes with usual course of care\n* Traumatic brain injury or any condition that would preclude the ability to comply with post-operative guidelines\n* Cartilage lesion finding in the involved shoulder that would interfere with usual course of care\n* Known pregnancy at time of imagining and\u002For surgery based upon standard of care testing procedures\n* Any issue with the contralateral shoulder that would preclude participation in research procedures\n* Any condition in the opinion of the investigator\u002Fclinician that would preclude or limit full participation in study activities\n* Absence of a fixed address or no means of contact\n* Known inability to be available at all follow-up time points\n* Does not plan to return to pre-injury levels of work, sports or military duty","17 Years","50 Years",{"count":400,"type":20},450,"This clinical trial will determine the outcome trajectories of common surgeries (arthroscopic Bankart repair with remplissage of a Hill-Sachs lesion, open Bankart, Latarjet) with post-operative rehabilitation and identification of prognostic factors among patients with acute or recurrent anterior shoulder instability with subcritical bone loss. The results of the study assist in optimizing time to return to military duty, work and sports, and patient-reported physical function for military personnel and civilians with traumatic anterior shoulder instability and 10-20% glenoid bone loss. This study will provide a critical clinical advancement of a previously unaddressed and common clinical scenario.",[403,404,405],"Shoulder Dislocation","Glenohumeral Dislocation","Anterior Shoulder Dislocation",[407,408,409,410,411],"Anterior Shoulder Instability","Glenoid Bone Loss","Stabilization Surgery","Return to Duty or Sport","Rehabilitation",{"date":326,"type":31},{"date":414,"type":31},"2022-01-24",{"date":416,"type":20},"2027-09-30",{"name":37,"class":38},15,{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":103,"minAge":17,"maxAge":245,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100566255","effectiveness-of-nurse-conducted-brief-intervention-ncbi-supplemented-with-mobile-for-preventing-alcohol-use-disorders-100566255","NCT06652802","Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile for Preventing Alcohol Use Disorders","Effectiveness of Nurse-Conducted Brief Intervention (NCBI) Supplemented With Mobile-based Application for Monitoring and Relapse Prevention in Patients With Alcohol Use Disorders: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Male patients.\n* Aged between 18 and 59 years.\n* Diagnosis of alcohol dependence use disorder based on ICD-10 criteria.\n* Patients with an Android smartphone and the ability to use mobile application.\n\nExclusion Criteria:\n\n* Female patients\n* Comorbid other substance abuse, except tobacco.\n* Comorbid major mental illness \u002Fphysical illness.",{"count":427,"type":20},74,[23],"The study is aimed to find out that combining Nurse-Conducted Brief Intervention (NCBI) with a Smart Mobile is better than Nurse-Conducted Brief Intervention (NCBI) only in preventing relapse among Alcohol Use Disorder patients. The high relapse rates among alcohol disorder patients may be benefitted by new technology using application for improved outcomes in managing and preventing alcohol addiction relapse.",[431],"Alcohol Use Disorder (AUD)",[433,434,435,436,437],"Alcohol Use Disorders (AUDs),","A Randomized controlled trial","Gastroenterology,","CIWA,","Nurse-Conducted Brief Intervention (NCBI)","2026-06-03",{"date":440,"type":31},"2026-06-05",{"date":442,"type":20},"2026-12-01",{"date":444,"type":20},"2028-06-30",{"name":37,"class":38},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":103,"minAge":17,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":21,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":468,"leadSponsor":469,"locationsCount":64},"100553619","effect-of-yoga-on-reducing-craving-in-tobacco-dependent-individuals-100553619","NCT06488443","Effect of Yoga on Reducing Craving in Tobacco Dependent Individuals","Randomized Control Study to Study the Effect of Yoga on Reducing Craving in Tobacco Dependent Individuals Who Want to Quit Tobacco Use","Inclusion Criteria:\n\n* -Tobacco dependent individuals (Fagerstrom test for tobacco dependence score more than or equal to 4)\n\n  * -Men aged 18 to 65 years\n  * -Recruited from Rural community health and training centre, Mugalur, Tobacco cessation centre and OPDs of Department of general medicine, pulmonary medicine, cardiology, oncology, ENT and dental surgery and other superspeciality OPD at SJMCH\n\nExclusion Criteria:\n\nPatients with recent alcohol use (last 3 months) and use of other drugs of abuse\n\n* -Patients with clinical diagnosis of Intellectual disability\n* -Comorbid Major mental illness including Dementia, Psychosis, Recurrent depressive disorder, Bipolar affective disorder, OCD, generalized anxiety disorder, Panic disorder and Phobias, diagnosed within the last 6 months.\n* -Patients with recent MI and stroke in the last 3 months or those physically unable to perform the yoga postures due to physical disabilities determined by clinical interview.\n\n  * -Patients with severe hypertension(SBP≥180mmHg and BP≥120mmHg)\n  * -Patients with seizures disorder\n  * -Patients with COPD(GOLD-2,3 and 4)","65 Years",{"count":455,"type":20},96,[23],"Yoga is a culturally acceptable practice that can reduce craving and help people quit tobacco. There is a need to evaluate the feasibility of implementation of a well- designed yoga protocol to address craving in individuals who use tobacco in India.",[459],"Tobacco Dependence",[461,462,463,464],"Tobacco dependence","Smoking","Craving","Fagerstorm test",{"date":440,"type":31},{"date":467,"type":31},"2024-11-01",{"date":174,"type":20},{"name":37,"class":38},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":477,"enrollmentInfo":478,"targetDuration":4,"studyType":21,"phases":479,"briefSummary":480,"conditions":481,"keywords":484,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":489,"leadSponsor":491,"locationsCount":64},"100552533","feasibility-and-acceptability-of-mobile-mental-health-app-for-sz-and-sza-100552533","NCT06474325","Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA","Feasibility and Acceptability of Mobile Mental Health Application for the Improvement of Medication Adherence in Persons With Schizophrenia(SZ) and Schizoaffective Disorder(SZA)","Inclusion Criteria:\n\n1. Persons diagnosed with schizophrenia and schizoaffective disorder and are in remission for past two months.\n2. Age 18-60 years of any gender.\n3. Able to read and understand Malayalam\u002F English\n\nExclusion Criteria:\n\n1. Patients who have active psychotic or mood symptoms.\n2. History of substance use (except nicotine)\n3. Having any serious physical illness. -","60 Years",{"count":371,"type":20},[23],"A new mental health application will be developed for persons with schizophrenia and schizoaffective disorder. The aim is to look at whether it is feasible to use a mobile health application for improving medication adherence in persons with schizophrenia and schizoaffective disorder and whether it is acceptable to that population.",[482,483],"Schizophrenia","Schizo Affective Disorder",[482,483,485,486],"Adherence","Mobile app",{"date":440,"type":31},{"date":442,"type":20},{"date":490,"type":20},"2028-05-31",{"name":37,"class":38},{"id":493,"slug":494,"hasResults":12,"nctId":495,"briefTitle":496,"officialTitle":497,"acronym":498,"eligibilityCriteria":499,"healthyVolunteers":12,"sex":16,"minAge":104,"maxAge":500,"enrollmentInfo":501,"targetDuration":4,"studyType":298,"phases":4,"briefSummary":502,"conditions":503,"keywords":505,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":39},"100116157","mechanisms-underlying-impaired-diabetic-wound-healing-100116157","NCT00777712","Mechanisms Underlying Impaired Diabetic Wound Healing","Mechanisms Underlying Impaired Wound Healing","WoundVAC","Inclusion Criteria:\n\n* Ages 21-80\n* Chronic Wound (present \\>4 weeks)\n* Diabetic \\& Non-diabetic\n* Adult surgical wounds\n\nExclusion Criteria:\n\n* Inability to consent\n* Pregnant women\n* Therapeutically immunocompromised\n* Individuals defined in 45 CFR 46 Subparts B,C, and D, nor from any other population considered vulnerable 2.9","80 Years",{"count":134,"type":20},"The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals with diabetes. Biology of normal (peripheral blood derived cells) versus wound derived cells will also be studied.",[504],"Non-healing Wound",[506,507,508,509,510,511],"Wound healing","diabetes","inflammatory cell","monocyte","leukocyte","macrophage",{"date":440,"type":31},{"date":514,"type":31},"2008-09-01",{"date":516,"type":20},"2030-12-31",{"name":37,"class":38},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":453,"enrollmentInfo":525,"targetDuration":4,"studyType":21,"phases":527,"briefSummary":528,"conditions":529,"keywords":532,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":538,"leadSponsor":539,"locationsCount":64},"100639440","modified-coronally-advanced-tunnel-for-mandibular-lingual-root-coverage-100639440","NCT07590960","Modified Coronally Advanced Tunnel for Mandibular Lingual Root Coverage","Clinical Outcomes of Modified Coronally Advanced Tunnel Technique With Deepithelialized Connective Tissue Graft for Mandibular Lingual Root Coverage: A Case Series","Inclusion Criteria:\n\n* Age 18-65 years\n* Single or multiple Cairo RT1 lingual gingival recessions ≥3 mm on mandibular incisors, canines, or premolars\n* Identifiable CEJ on the lingual aspect\n* Vital uniradicular teeth\n* Full-mouth plaque score \\\u003C20%\n* Smokes less than 10 cigarettes per day\n* Adequate mouth opening for lingual access\n* Sufficient palatal donor tissue thickness (≥2 mm at 2-3 mm from gingival margin)\n\nExclusion Criteria:\n\n* Positive urine pregnancy test or self-reported lactation\n* Smoker more than 10 cigarettes per day\n* Uncontrolled systemic diseases, at the discretion of the PI (diabetes HbA1c \\>7%, cardiovascular disease, immunocompromised)\n* Use of medications affecting periodontal tissues (phenytoin, calcium channel blockers, immunosuppressants)\n* Use of blood thinners\n* Previous root coverage surgery at treated sites\n* Teeth with cervical restorations or caries on lingual surfaces\n* Inadequate attached gingiva (\\\u003C1 mm)\n* Prominent lingual frenum attachment requiring frenectomy",{"count":526,"type":20},20,[23],"This study will follow adults who have gum recession on the tongue side of the lower teeth. Participants will receive a gum surgery called the Modified Coronally Advanced Tunnel technique with a connective tissue graft taken from the roof of the mouth. The study will include 20 participants and will follow them for up to 24 months after surgery. The main outcome is how much of the exposed root is covered 6 months after surgery. The study will also measure gum thickness, gum width, tooth sensitivity, healing, patient comfort, satisfaction, and three-dimensional soft tissue changes using intraoral scans.",[530,531],"Gingival Recession","Mucogingival Deformity - Insufficient Keratinized Tissue",[530,533,534],"Tissue Grafts","Tooth Sensitivity","2026-06-02",{"date":383,"type":31},{"date":386,"type":20},{"date":62,"type":20},{"name":37,"class":38},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":215,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":547,"targetDuration":4,"studyType":21,"phases":549,"briefSummary":550,"conditions":551,"keywords":553,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":64},"100609683","effects-of-operational-naps-on-blood-pressure-and-performance-among-night-shift-workers-100609683","NCT07217769","Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers","EONN","Inclusion Criteria:\n\n* non-pregnant adults (\\>18 years of age)\n* certified public safety\u002Fhealthcare shift worker\n* is an active shift worker\n* resides within the Western Pennsylvania region within reasonable driving distance\n\nExclusion Criteria:\n\n* current use of medication for cardiovascular disease (e.g., hypertension)\n* prior or current diagnosis of sleep apnea, narcolepsy, restless leg syndrome, ischemic heart disease, heart failure, stroke, chronic kidney disease, chronic liver disease, rheumatologic disease requiring prescription medication, and cancer requiring treatment in past 2 years\n* undiagnosed severe sleep apnea (Apnea-Hypopnea Index \\>30) based on at-home test\n* Abstains from caffeine or reports adverse effects from caffeine use",{"count":548,"type":20},130,[23],"Night shift work schedules disrupt sleep and have a negative impact on cardiovascular health. Most who work in public safety occupations and in healthcare work night shifts. These workers experience abnormal blood pressure during night shifts and are at greater risk of cardiovascular disease. Napping during night shifts can help to restore blood pressure patterns to a more normal pattern and may help to reduce risk of cardiovascular disease. Naps may also have an impact on alertness and performance immediately upon waking. The overarching goal of this study is to determine which duration of a nap taken during simulated night shift work has the greatest impact blood pressure and post-nap performance.\n\nResearchers will compare 5 nap durations to see which has the greatest impact on blood pressure patterns and post-nap psychomotor performance.\n\nResearchers hypothesize that longer naps will lead to improved blood pressure outcomes and shorter naps will contribute to better performance after waking.\n\nFindings will help employers and employees who work night shifts determine how best to incorporate brief naps during night shift work.",[552],"Shift Work",[554,82,555,556,557,558,559],"Night shift","Napping","Blood pressure","Psychomotor performance","Sleep inertia","Caffeine",{"date":438,"type":31},{"date":562,"type":31},"2026-05-07",{"date":564,"type":20},"2030-08-31",{"name":37,"class":38},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":572,"eligibilityCriteria":573,"healthyVolunteers":215,"sex":16,"minAge":574,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":21,"phases":577,"briefSummary":578,"conditions":579,"keywords":583,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":64},"100595961","pilot-trial-of-clinic-based-dating-violence-prevention-program-for-adolescents-and-caregivers-100595961","NCT07039253","Pilot Trial of Clinic-based Dating Violence Prevention Program for Adolescents and Caregivers","Engaging Together for Healthy Relationships Version 2.0: Multisite Pilot Intervention Trial","ETHR2","Inclusion Criteria\n\nProviders:\n\n1. Sees patient at an eligible primary care clinic\n2. Speaks and understands English\n3. Age 18 or older\n4. Identifies as a pediatrician, nurse practitioner, physician assistant (pediatric primary care healthcare provider)\n\nAdolescents\n\n1. Age 12 to 16\n2. Attending an upcoming well-child visit from a provider enrolled in the study\n3. Caregiver who is accompanying well-child visit with adolescent is also participating\n4. Speaks and understands English\n\nParents\n\n1. Is parent or primary caregiver for an adolescent age 12 to 16\n2. Adolescent has an upcoming well-child visit with a provider enrolled in the study\n3. Accompanying child to the well-visit\n4. Adolescent is interested and eligible to participate in study\n5. Speaks and understand English\n\nExclusion Criteria:\n\n* Unable to assent\u002Fconsent\n* Does not meet inclusion criteria","12 Years",{"count":576,"type":20},120,[23],"ETHR V 2.0 pilot trial is a one-arm, multi-site pilot trial to assess the acceptability and feasibility of Engaging Together for Healthy Relationships, a caregiver-adolescent dating violence prevention program delivered within pediatric primary care.",[580,581,582],"Dating Violence","Parent","Primary Care",[584,585,586,587],"dating violence prevention","parental monitoring and communication","pilot trial","middle school",{"date":383,"type":31},{"date":590,"type":31},"2025-08-15",{"date":592,"type":20},"2027-06-15",{"name":37,"class":38},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":16,"minAge":574,"maxAge":17,"enrollmentInfo":601,"targetDuration":4,"studyType":21,"phases":603,"briefSummary":604,"conditions":605,"keywords":609,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":39},"100590134","transdiagnostic-sleep-and-circadian-intervention--bright-light-in-adolescents-with-elevated-depression-trans-cbl-100590134","NCT06963463","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression","Inclusion Criteria:\n\n* Adolescents (12-18)\n* Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11\n* Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2.\n* English language fluency and literacy sufficient to engage in study protocol.\n\nExclusion Criteria:\n\n* Evidence of obstructive sleep apnea,\n* Evidence of restless legs syndrome\n* Evidence of psychosis\n* Evidence of bipolar disorder\n* Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.",{"count":602,"type":20},90,[23],"The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.",[606,82,607,608],"Sleep Disturbance","Depression","Suicide",[610,611,612,613],"Sleep Disturbances","Objective Sleep","Subjective Sleep Difficulties","Minority Youth",{"date":383,"type":31},{"date":616,"type":31},"2025-05-06",{"date":618,"type":20},"2027-07-31",{"name":37,"class":38},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":16,"minAge":574,"maxAge":17,"enrollmentInfo":628,"targetDuration":4,"studyType":21,"phases":630,"briefSummary":631,"conditions":632,"keywords":635,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":39},"100579873","get-active-study-for-at-risk-youth-100579873","NCT06829953","Get ActivE Study for At-risk Youth","Geospatial and Ecological Momentary Assessment Technology and Activity Engagement for At-risk Youth (Get ActivE)","GetActivE","Inclusion Criteria:\n\n* Adolescents age 12-18\n* Current moderate to severe depression (PHQ-9-M \\> 11)\n* Current clinically significant anhedonia, operationalized as PHQ-9-M anhedonia item score \\> 1\n* English language fluency and literacy level sufficient to engage in study protocol\n* Willing to download the app on their smart phones\n\nExclusion Criteria:\n\n* Evidence of mania, psychosis, or developmental disability precluding comprehension of study procedures per electronic health record review and phone screen.",{"count":629,"type":20},75,[23],"The study will adapt and deploy a digital Behavioral Activation app with mobile sensing, supported by health coaches, that encourages youth to engage in positive activities. The study has the potential to offer a low-cost and scalable behavioral intervention that may decrease risk of suicide among at-risk youth. This research will examine specifically whether an intervention involving an app called Vira, combined with health coaching (GET ActivE) can improve enjoyment for teens coping with depression. Research participants will be randomly assigned to one of two study intervention. One study intervention involves a) downloading an app called Vira and engaging by responding to a daily question, and b) participating in a conversation via text, phone, or messages through an appt with a health coach. The health coach will use the Vira app and principles from evidence-based therapy and behavior change to provide users with insights to sustain well-being and better manage risk factors for suicidal thoughts and behaviors such as depressed mood and behavioral withdrawal. The second study intervention involves downloading an app called EARS and responding to a daily question.",[633,634],"Anhedonia","Depression and Suicide Ideation",[636,637,633,613,608],"Behavioral Activation","Health Coach",{"date":383,"type":31},{"date":640,"type":31},"2025-03-27",{"date":642,"type":20},"2026-12-31",{"name":37,"class":38},{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":650,"targetDuration":4,"studyType":21,"phases":652,"briefSummary":653,"conditions":654,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":656,"startDateStruct":657,"completionDateStruct":659,"leadSponsor":660,"locationsCount":64},"100551666","testing-an-intergenerational-model-of-suicide-risk-in-mother-child-dyads-100551666","NCT06463054","Testing an Intergenerational Model of Suicide Risk in Mother-child Dyads","Inclusion Criteria:\n\n* Biological mothers with legal custody of target child between 9-11\n* Confirmed lifetime Biological mothers with legal custody of target child between 9-11\n* Confirmed lifetime history of suicidal behavior for mothers of suicidal behavior for mothers\n\nExclusion Criteria:\n\n* Any mothers and children with major medical illnesses that might be associated with organic personality changes or ER difficulties (e.g. Parkinson's Disease, seizure disorders)\n* Cardiac nervous system abnormalities that would influence physiological readings\n* Previous DBT (Dialectical Behavior Therapy) in the last six months",{"count":651,"type":20},150,[23],"The investigators are interested in learning more about how the role of mothers' emotions has on the transmission of suicide risk to children. Eligible participants will be invited to participate in a baseline assessment, and 4 follow-up assessments in the next year. This research study is a randomized control trial. Participants that choose to enroll are randomly assigned, that is by chance (like by flipping a coin) to receive DBT Skills Training or treatment as usual (TAU). Participants may also be selected for DBT skills training, it which would occur once a week for 6 months.",[655],"Emotion Regulation",{"date":383,"type":31},{"date":658,"type":31},"2024-04-01",{"date":331,"type":20},{"name":37,"class":38},""]